Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 863-873

  Sadler, T M ^a   Gavriil, M ^a   Annable, T ^a,b   Frost, P ^a,c   Greenberger, L M ^a,d   Zhang, Y ^a  

^a PFIZER INC   (United States)

^b ImClone Systems Incorporated ^*  (United States)

^c ELI LILLY AND COMPANY   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PIPENDOXIFENE; RALOXIFENE; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; TRANSCRIPTION INITIATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENETIC MARKERS; HUMANS; INDOLES; MICE; MICE, NUDE; OVARIECTOMY; PIPERIDINES; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SIROLIMUS; THYMECTOMY; TRANSFECTION;

EID: 33751117795     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01170     Document Type: Article

References (44)

1. American Cancer Society http://www.cancer.org (accessed Feb. 2006).
2. Asnaghi L, Bruno P, Priulla M & Nicolin A 2004 mTOR: a protein kinase switching between life and death. Pharmacological Research 50 545-549.
3. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR & Kirschmeier P 2005 The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. Journal of Biological Chemistry 280 31101-31108.
4. Bergh J, Jonsson PE, Glimelius B, Nygren P; SBU-group 2001 A systematic overview of chemotherapy effects in breast cancer. Acta Oncologica 40 253-281.
5. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S & Lane HA 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical Cancer Research 11 5319-5328.
6. Carraway H & Hidalgo M 2004 New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Research 6 219-224.
7. Choi JH, Bertram PG, Drenan R, Carvalho J, Zhou HH & Zheng XFS 2002 The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase. EMBO Reports 3 988-994.
8. Dancey JE 2002 Clinical development of mammalian target of rapamycin inhibitors. Hematology-Oncology Clinics of North America 16 1101-1114.
9. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA & Hidalgo M 2004 Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clinical Cancer Research 10 8059-8067.
10. Dennis PB & Thomas G 2002 Target of rapamycin. Current Biology 12 R269.
11. Dutcher JP 2004 Mammalian target of rapamycin (mTOR) inhibitors. Current Oncology Reports 6 111-115.
12. Elit L 2002 CCI-779 Wyeth. Current Opinion in Investigational Drugs 3 1249-1253.
13. Fingar DC & Blenis J 2004 Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 3151-3171.
14. Germain P, Altucci L, Bourguet W, Rochette-Egly C & Gronemeyer H 2003 Nuclear receptor superfamily: principles of signaling. Pure and Applied Chemistry 75 1619-1664.
15. Gibbons JJ, Discafani J, Peterson R, Hernandez R, Skotnicki J & Frost P 2000 The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proceedings of American Association for Cancer Research Annual Meeting 41 301.
16. Gingras AC, Raught B & Sonenberg N 2004 mTOR signaling to translation. Current Topics in Microbiology and Immunology 279 169-197.
17. Gougelet A, Boucher C, Marsaud W, Maillard S, Mueller SO, Korach KS & Renoir JM 2005 Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. Journal of Steroid Biochemistry Molecular Biology 94 71-81.
18. Greenberger LM, Annable T, Collins KI, Komm BS, Lyttle CR, Miller CP, Satyaswaroop PG, Zhang Y & Frost P 2001 A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl] -1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Clinical Cancer Research 7 3166-3177.
19. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou JN, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476.
20. Horwitz KB 1993 Mechanisms of hormone resistance in breast cancer. Breast Cancer Research and Treatment 26 119-130.
21. Huang S, Bjornsti MA & Houghton PJ 2003 Rapamycins: mechanism of action and cellular resistance. Cancer Biology and Therapy 2 222-232.
22. Ivery MT & Weiler L 1997 Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex. Bioorganic and Medicinal Chemistry 5 217-232.
23. Jaiyesimi I, Buzdar AU, Decker DA & Hortobagyi GN 1995 Use of tamoxifen for breast cancer: twenty-eight years later. Journal of Clinical Oncology 13 513-529.
24. Johnson L, Gibson A, Maung K & O'Shaughnessy J 2002 Highlights from the 38th annual meeting of the American Society of Clinical Oncology. Clinical Breast Cancer 3 174-179.
25. Johnston SRD 2005 Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clinical Cancer Research 11 889S-899S.
26. Jordan CV 1999 How does tamoxifen work? In Tamoxifen for the Treatment and Prevention of Breast Cancer, p 260. Ed. CV Jordan. Melville, NY: PRR Publishers.
27. Kaufmann M 1997 A review of endocrine options for the treatment of advanced breast cancer. Oncology 54 2-5.
28. Kim R, Osaki A & Toge T 2001 A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein. International Journal of Oncology 19 1075-1080.
29. Lee H, Jiang F, Wang Q, Nicosia SV, Yang J, Su B & Bai W 2000 MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Molecular Endocrinology 14 1882-1896.
30. McKenna NJ & O'Malley BW 2001 Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Annals of the New York Academy of Sciences 949 3-5.
31. Martin LA, Farmer I, Johnston SRD, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biochemical Chemistry 278 30458-30468.
32. Mollison KW, Fey TA, Gauvin DM, Sheets MP, Smith ML, Pong M, Krause R, Miller L, Or YS, Kawai M et al. 1998 Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Current Pharmaceutical Design 4 367-379.
33. Mourits MJE, Vries EGE, Willemse PHB, Ten Hoor KA, Hollema H & Van der Zee AGJ 2001 Tamoxifen treatment and gynecologic side effects: a review. Obstetrics and Gynecology 97 855-866.
34. Owa T, Yoshino H, Yoshimatsu K & Nagasu T 2001 Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Current Medicinal Chemistry 8 1487-1503.
35. Prichard MN & Shipman CJ 1990 A three-dimensional model to analyze drug-drug interactions. Antiviral Research 14 181-206.
36. Punt CJ, Boni J, Bruntsch U, Peters M & Thielert C 2003 Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Annals of Oncology 14 931-937.
37. Reid G, Denger S, Kos M & Gannon F 2002 Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cellular and Molecular Life Sciences 59 821-831.
38. Ring A & Dowsett M 2004 Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11 643-658.
39. Rohde J, Heitman J & Cardenas ME 2001 The TOR kinases link nutrient sensing to cell growth. Journal of Biological Chemistry 276 9583-9586.
40. Smith IC, Hutcheon AW & Keys SD 2000 Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer. Current Pharmaceutical Design 6 327-343.
41. Society AC Cancer Facts and Figures 2005 Atlanta: American Cancer Society;2005.
42. Vogt PK 2001 PI 3-kinase, mTOR, protein synthesis and cancer. Trends in Molecular Medicine 7 482-484.
43. Yu K, Toral-Barza L, Discafani C. Zhang WG, Skotnicki J, Frost P & Gibbons JJ 2001 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Related Cancer 8 249-258.
44. Zhang Y, Sadler T, Annable T, Achilleos M, Frost P & Greenberger LM 2003 Combination therapy for treating breast cancer using the antiestrogen, ERA-923 and the mTOR inhibitor, CCI-779. Proceedings of American Association for Cancer Research 44 739.